Abraxis Bioscience, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Abraxis Bioscience, Inc.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
- Other Names / Subsidiaries
- Shimoda Biotech Ltd.